Detailed Information on Publication Record
2001
Aktivace autologních transplantátů hematopoetických kmenových buněk interleukinem 2
HÁJEK, Roman, Zdeněk KOŘÍSTEK, J. VINKLÁRKOVÁ, E. JANOVSKÁ, Martin KLABUSAY et. al.Basic information
Original name
Aktivace autologních transplantátů hematopoetických kmenových buněk interleukinem 2
Name in Czech
Aktivace autologních transplantátů hematopoetických kmenových buněk interleukinem 2
Name (in English)
Activation of autologous hematopoietic stem cell transplants with interleukin-2
Authors
HÁJEK, Roman (203 Czech Republic, guarantor), Zdeněk KOŘÍSTEK (203 Czech Republic), J. VINKLÁRKOVÁ (203 Czech Republic), E. JANOVSKÁ (203 Czech Republic), Martin KLABUSAY (203 Czech Republic), M. DOUBEK (203 Czech Republic), D. DVOŘÁKOVÁ (203 Czech Republic), L. BOURKOVÁ (203 Czech Republic), L. DUŠEK (203 Czech Republic), J. ADLER (203 Czech Republic), Jiří MAYER (203 Czech Republic) and Jiří VORLÍČEK (203 Czech Republic)
Edition
Časopis lékařů českých, Praha, Česká lékařská společnost J. Ev. Purkyně, 2001, 0008-7335
Other information
Language
Czech
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
Organization unit
Faculty of Medicine
Keywords (in Czech)
IL-2; autologní transplantace; kmenové buňky
Keywords in English
interleukin-2; autologous transplantation; stem cell
Změněno: 23/6/2009 17:20, Mgr. Anna Potáčová, Ph.D.
V originále
V publikaci je popsána metodika a výsledky aktivace hematopoetických buněk pomocí IL-2.
In English
Recent findings of the role of the immunity in eradication of residual tumour tissue after autologous transplantation rejection leading to extensive studies on T-cell mediated specific antitumor effects or nonspecific NL-cell mediated anticancer effects. We have evaluated on the methods of adoptive cell therapy IL-2 activation of autologous graft in the preclinical conditions. In laboratory conditions we have manipulated with autologous grafts form patients suffering with chronic myelocytic leukemia and patients suffering with multiple myeloma.We have proved the possibility to use IL-2 activated autologous graft in the clinical conditions. Based on our preclinical results experimental clinical trials have been initiated in patients suffering from chronic myelocytic leukemia and multiple myeloma.